News - Ariad Pharmaceuticals

Filter

Current filters:

Ariad Pharmaceuticals

Popular Filters

Ariad Pharma plans commercialization of Iclusig in Australia

Ariad Pharma plans commercialization of Iclusig in Australia

28-01-2014

US specialty pharma firm Ariad Pharmaceuticals has signed an agreement with Specialised Therapeutics…

Ariad PharmaceuticalsAsia-PacificAustraliaIclusigLicensingOncologyPharmaceuticalSpecialised Therapeutics Australia

EMA/CHMP recommends changes in use of Iclusig to minimize risk of blood clots

EMA/CHMP recommends changes in use of Iclusig to minimize risk of blood clots

23-11-2013

The European Medicines Agency’s Committee for Medicinal Products for Human Use has made a number of…

Ariad PharmaceuticalsEuropeIclusigOncologyPharmaceuticalRegulation

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

EMA Pharmacovigilance unit updates on Iclusig, diacerein and acipimox

09-11-2013

At its November 4-7 meetings, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

acipimoxAnti-Arthritics/RheumaticsAriad PharmaceuticalsCardio-vasculardiacereinEuropeIclusigOncologyPharmaceuticalRegulation

Ariad Pharma “temporarily” suspends only marketed drug Iclusig in USA

Ariad Pharma “temporarily” suspends only marketed drug Iclusig in USA

01-11-2013

US drugmaker Ariad Pharmaceutical says it temporarily suspending the marketing and commercial distribution…

Ariad PharmaceuticalsIclusigMarkets & MarketingNorth AmericaOncologyPharmaceuticalRegulation

Ariad stops Ph III Iclusing trial on blood clot woes

18-10-2013

US biotech firm Ariad Pharmaceuticals’took another tumble, falling 35% to $2.91, as the company said…

Ariad PharmaceuticalsBiotechnologyIclusigNorth AmericaOncologyRegulationResearch

US FDA investigating stricken Ariad over Iclusig safety concerns

US FDA investigating stricken Ariad over Iclusig safety concerns

14-10-2013

The US FDA is investigating an increasing frequency of reports of serious and life-threatening blood…

Ariad PharmaceuticalsIclusigNorth AmericaOncologyPharmaceuticalRegulation

FDA clinical hold on Iclusig sees Ariad stock go into free-fall

FDA clinical hold on Iclusig sees Ariad stock go into free-fall

10-10-2013

US drugmaker Ariad Pharmaceuticals saw its shares plunge 59% to $6.99 yesterday, wiping $2 billion off…

Ariad PharmaceuticalsBiotechnologyIclusigNorth AmericaOncologyRegulationResearch

Ariad's cancer drug Iclusig granted marketing authorization in the EU for leukemia

02-07-2013

USA-based Ariad Pharmaceuticals (Nasdaq: ARIA) yesterday (July 2) announced that it has been granted…

Ariad PharmaceuticalsIclusigMarkets & MarketingOncologyPharmaceutical

US FDA approvals for Signifor, raxibacumab and Iclusig

17-12-2012

In a flurry of activity from the US Food and Drug Administration on Friday, the agency - which looks…

Antibiotics and Infectious diseasesAriad PharmaceuticalsGlaxoSmithKlineIclusigNorth AmericaNovartisOncologyPharmaceuticalRare diseasesraxibacumabRegulationSignifor

Ariad Pharma gets accelerated EU review for ponatinib

31-08-2012

USA-based Ariad Pharmaceuticals (Nasdaq: ARIA) has filed a Marketing Authorization Application for its…

Ariad PharmaceuticalsEuropeOncologyPharmaceuticalponatinibRegulation

FDA calls for more trials on Merck & Co and Ariad's sarcoma drug ridaforolimus

06-06-2012

US drug giant Merck & Co (NYSE: MRK) has received a complete response letter from the US Food and Drug…

Ariad PharmaceuticalsMerck & CoNorth AmericaOncologyPharmaceuticalRegulationridaforolimusTaltorvic

Thumbs down for Merck & Co and Ariad sarcoma drug Taltorvic from FDA advisory

21-03-2012

The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) yesterday voted by 13 to…

Ariad PharmaceuticalsMerck & CoNorth AmericaOncologyPharmaceuticalRegulationridaforolimusTaltorvic

Highlights of ASH meeting

13-12-2011

Among presentations at this year’s Annual Meeting of the American Society of Hematology (ASH), held…

AEterna ZentarisAriad PharmaceuticalsBiotechnologyblinatumomabMicrometOncologyperifosinePharmaceuticalPharmacyclicsponatinibResearch

Exec appointments at SkyePharma, Impax, Ariad and Regeneron

07-09-2011

UK-based drug delivery specialist SkyePharma (LSE: SKP) has appointed Pierre Delavaud as executive vice…

Ariad PharmaceuticalsGenericsImpax LaboratoriesManagementPharmaceuticalRegeneronSkyepharma

AstraZeneca gets EU approval for Axanum; Merck & Co files ridaforolimus with EMA

02-08-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has received approval in…

Ariad PharmaceuticalsAstraZenecaAxanumCardio-vascularEuropeMerck & CoOncologyPharmaceuticalRegulationridaforolimus

More highlights from ASCO

07-06-2011

The ongoing annual meeting of the American Society of Clinical Oncology (ASCO) saw another batch of good…

Ariad PharmaceuticalsAstellas PharmaMedivationMerck & CoOncologyPharmaceuticalponatinibResearchridaforolimus

ARIAD in three exclusive out-licensing deals for ARGENT cell-signaling regulation technology

21-04-2011

USA-based ARIAD Pharmaceuticals (Nasdaq: ARIA) has announced execution of three exclusive out-license…

Ariad PharmaceuticalsLicensingPharmaceuticalResearch

Back to top